
Alnylam Pharmaceuticals
Updated August 2022.
94%
Employees say this is a great place to work
Company Overview
About The Company
Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA™ (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Novartis.
COMPANY SIZE
1,506 U.S.-based Employees
(Large)
INDUSTRY
Biotechnology & Pharmaceuticals
HQ Location
Cambridge, MA, US
Employee Demographics
Tenure
Company Culture at Alnylam Pharmaceuticals
The employee experience below at Alnylam Pharmaceuticals, compared to a typical company.
Learn More94% of employees at Alnylam Pharmaceuticals say it is a great place to work compared to 57% of employees at a typical U.S.-based company.
97%
When I look at what we accomplish, I feel a sense of pride.
96%
People here are willing to give extra to get the job done.
96%
I'm proud to tell others I work here.
96%
I feel good about the ways we contribute to the community.
96%
When you join the company, you are made to feel welcome.
Why Work at Alnylam Pharmaceuticals?
See what employees say about what makes Alnylam Pharmaceuticals a great workplace. These words are drawn from employee comments on the Trust Index™ survey.
Life at Alnylam Pharmaceuticals
Best Workplaces Lists
Great Place To Work® is proud to recognize Alnylam Pharmaceuticals
Don't See Your Company Listed?
Nominate your company today to join Certification Nation

CONNECT